CO6210727A2 - Derivados de 8 etinilxantina como antagonistas de receptores de a2a selectivos - Google Patents
Derivados de 8 etinilxantina como antagonistas de receptores de a2a selectivosInfo
- Publication number
- CO6210727A2 CO6210727A2 CO09066323A CO09066323A CO6210727A2 CO 6210727 A2 CO6210727 A2 CO 6210727A2 CO 09066323 A CO09066323 A CO 09066323A CO 09066323 A CO09066323 A CO 09066323A CO 6210727 A2 CO6210727 A2 CO 6210727A2
- Authority
- CO
- Colombia
- Prior art keywords
- substituted
- methyl
- amino
- hydroxyl
- carboxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
1.- Un compuesto representado por la fórmula (la), y sales, isómeros, diaestereómeros o enantiómeros farmacéuticamente aceptables del mismoen donde, R2 es hidrógeno, metilo, NR6R7 o R2 es alquilo (C2-C4), alquenilo (C2-C4) o alquinilo (C2-C4), oR2 es metilo que está sustituido con un residuo seleccionado de ciano, carboxi, cicloalquilo (C3-C5), alcoxi (C1-C2)-carbonilo, alquil (C1-C2)-carbonilo, monoalquil(C1-C2)-amino, dialquil (C1-C2)-amino, heterociclilo con anillo de 3 a 5 átomos y heteroarilo con anillo de 5 a 6 átomos, o R2 es etilo, que está sustituido en uno o más sitios, del mismo modo o de diferente manera, con flúor, cloro, bromo, ciano, metilcarbonilo, metoxicarbonilo, monoalquil(C1-C2)-amino, dialquil(C1-C2)-amino, -OR8, heterociclilo que contiene oxígeno con anillo de 3 a 5 átomos, hidroxilo o un éster de fosfato o un éster de aminoácido de dicho grupo hidroxilo, o R2 es propilo o butilo, que está sustituido en uno o más sitios, del mismo modo o diferente, con flúor, cloro, bromo, ciano, -carboxi, -OR8, hidroxilo o un éster de fosfato o un éster de aminoácido de dicho grupo hidroxilo, R3 es metilo, propargilo, butinilo o cianometilo; R4 es tien-3-ilo, furan-3-ilo o imidazolilo, cada uno puede sustituirse con uno o más sustituyentes seleccionados de halógeno, metilo y metoxi, o R4 es un fenilo que está sustituido en la posición meta y/o en para a su posición de unión al triple enlace con uno o dos grupos seleccionados de halógeno, amino, -OR5 y metilo, oR4 es un fenilo que está condensado en la posición meta y para a un segundo anillo heterocíclico de cinco o seis miembros que contiene uno o más átomos de oxígeno, formándose así un sistema de anillo bicíclico que puede estar sustituido con uno o dos residuos seleccionados de metoxi, metilo o hidroxilo; R5 es un hidrógeno, alquilo (C1-C4), alquenilo (C2-C4), alquinilo (C2-C4), o R5 es alquilo (C1-C5) sustituido en uno o más sitios, del mismo modo o de diferente manera, con halógeno, furan-3-ilo, metoxi, etoxi, carboxi, hidroxilo o un éster de fosfato o aminoácido del mismo, o -NR6R7, ...
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06026739A EP1939197A1 (en) | 2006-12-22 | 2006-12-22 | 8-ethinylxanthine derivatives as selective A2A receptor antagonists |
| US9452407P | 2007-06-20 | 2007-06-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6210727A2 true CO6210727A2 (es) | 2010-10-20 |
Family
ID=37733427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO09066323A CO6210727A2 (es) | 2006-12-22 | 2009-06-25 | Derivados de 8 etinilxantina como antagonistas de receptores de a2a selectivos |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8044061B2 (es) |
| EP (2) | EP1939197A1 (es) |
| CN (1) | CN101631788A (es) |
| AR (1) | AR064657A1 (es) |
| AU (1) | AU2007338413A1 (es) |
| BR (1) | BRPI0720419A2 (es) |
| CA (1) | CA2672692A1 (es) |
| CO (1) | CO6210727A2 (es) |
| RU (1) | RU2009127883A (es) |
| UY (1) | UY30835A1 (es) |
| WO (1) | WO2008077557A1 (es) |
| ZA (1) | ZA200902187B (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1781657T3 (da) * | 2004-02-14 | 2013-06-10 | Glaxosmithkline Ip Dev Ltd | Medikamenter med hm74a-receptor aktivitet |
| WO2011101861A1 (en) | 2010-01-29 | 2011-08-25 | Msn Laboratories Limited | Process for preparation of dpp-iv inhibitors |
| EP2465859A1 (en) | 2010-12-08 | 2012-06-20 | Life & Brain GmbH | 8-Triazolylxanthine derivatives, processes for their production and their use as adenosine receptor antagonists |
| US9221821B2 (en) | 2012-06-05 | 2015-12-29 | Forest Laboratories Holdings, Limited | Methods for the synthesis of 1,3-substituted aminouracils and other xanthine-related compounds |
| GB201311107D0 (en) * | 2013-06-21 | 2013-08-07 | Univ Edinburgh | Bioorthogonal methods and compounds |
| US10124003B2 (en) | 2013-07-18 | 2018-11-13 | Taiho Pharmaceutical Co., Ltd. | Therapeutic agent for FGFR inhibitor-resistant cancer |
| PL3023100T3 (pl) | 2013-07-18 | 2019-07-31 | Taiho Pharmaceutical Co., Ltd. | Lek przeciwnowotworowy do okresowego podawania inhibitora FGFR |
| GB2553684B (en) * | 2015-03-27 | 2020-06-03 | Latvian Inst Organic Synthesis | Ethynylxanthines, preparation and use for cancer treatment |
| WO2016159746A1 (en) | 2015-03-27 | 2016-10-06 | Latvian Institute Of Organic Synthesis | Novel ethynylxanthines, their preparation and use as inhibitors of matrix metalloproteinases and angiogenesis |
| GB2553686B (en) * | 2015-03-27 | 2020-06-03 | Latvian Inst Organic Synthesis | Ethynylxanthines, preparation and use as calcium ion channel modulators |
| AU2016240841C1 (en) | 2015-03-31 | 2018-05-17 | Taiho Pharmaceutical Co., Ltd. | Crystal of 3,5-disubstituted benzene alkynyl compound |
| PL3280417T3 (pl) * | 2015-04-08 | 2020-12-28 | Lewis And Clark Pharmaceuticals, Inc. | Podstawione ksantyną karbaminiany alkinylu/odwrócone karbaminiany jako antagoniści A<sub>2B</sub> |
| US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
| KR20240014585A (ko) | 2016-03-04 | 2024-02-01 | 다이호야쿠힌고교 가부시키가이샤 | 악성 종양 치료용 제제 및 조성물 |
| US11833151B2 (en) | 2018-03-19 | 2023-12-05 | Taiho Pharmaceutical Co., Ltd. | Pharmaceutical composition including sodium alkyl sulfate |
| US20240002416A1 (en) | 2020-10-15 | 2024-01-04 | Rheinische-Friedrich-Wilhelms-Universität Bonn | MRGPRX4 Agonists and Antagonists |
| CN115636831A (zh) * | 2022-10-27 | 2023-01-24 | 中国药科大学 | 稠合嘧啶二酮类化合物、其用途以及药物组合物 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5484920A (en) | 1992-04-08 | 1996-01-16 | Kyowa Hakko Kogyo Co., Ltd. | Therapeutic agent for Parkinson's disease |
| ATE218139T1 (de) | 1994-02-23 | 2002-06-15 | Kyowa Hakko Kogyo Kk | Xanthin-derivate |
| CA2369981A1 (en) | 1999-04-09 | 2000-10-19 | Cell Therapeutics, Inc. | Therapeutic compounds for inhibiting interleukin-12 signaling and methods for using same |
| MXPA03004926A (es) | 2001-02-14 | 2005-02-14 | Warner Lambert Co | Inhibidores de metaloproteinasas de matriz basados en pirimidinonas fusionadas. |
| NZ528216A (en) * | 2001-02-24 | 2006-12-22 | Boehringer Ingelheim Pharma | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
| AU2003253165A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Pyrimidine fused bicyclic metalloproteinase inhibitors |
| EP1615931A1 (en) | 2003-04-09 | 2006-01-18 | Biogen Idec MA Inc. | Triazolopyrazines and methods of making and using the same |
| US7834014B2 (en) | 2003-04-09 | 2010-11-16 | Biogen Idec Ma Inc. | A2a adenosine receptor antagonists |
| CN1972945A (zh) | 2004-04-02 | 2007-05-30 | 腺苷治疗有限责任公司 | A2a腺苷受体的选择性拮抗剂 |
| WO2006091896A2 (en) * | 2005-02-25 | 2006-08-31 | Adenosine Therapeutics, Llc | Pyridyl substituted xanthines |
| US7598379B2 (en) | 2005-02-25 | 2009-10-06 | Pgx Health, Llc | Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines |
| WO2006091897A2 (en) | 2005-02-25 | 2006-08-31 | Adenosine Therapeutics, Llc | Derivatives of 8-substituted xanthines |
| US7618962B2 (en) | 2005-02-25 | 2009-11-17 | Pgx Health, Llc | Pyrazolyl substituted xanthines |
-
2006
- 2006-12-22 EP EP06026739A patent/EP1939197A1/en not_active Ceased
-
2007
- 2007-12-19 AU AU2007338413A patent/AU2007338413A1/en not_active Abandoned
- 2007-12-19 BR BRPI0720419-1A patent/BRPI0720419A2/pt not_active Application Discontinuation
- 2007-12-19 WO PCT/EP2007/011172 patent/WO2008077557A1/en active Application Filing
- 2007-12-19 CA CA002672692A patent/CA2672692A1/en not_active Abandoned
- 2007-12-19 CN CN200780047483A patent/CN101631788A/zh active Pending
- 2007-12-19 EP EP07856895.3A patent/EP2097415B1/en active Active
- 2007-12-19 RU RU2009127883/04A patent/RU2009127883A/ru not_active Application Discontinuation
- 2007-12-21 US US11/963,477 patent/US8044061B2/en active Active
- 2007-12-21 UY UY30835A patent/UY30835A1/es unknown
- 2007-12-21 AR ARP070105825A patent/AR064657A1/es not_active Application Discontinuation
-
2009
- 2009-03-26 ZA ZA200902187A patent/ZA200902187B/xx unknown
- 2009-06-25 CO CO09066323A patent/CO6210727A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200902187B (en) | 2009-11-25 |
| WO2008077557A1 (en) | 2008-07-03 |
| RU2009127883A (ru) | 2011-01-27 |
| US20080221134A1 (en) | 2008-09-11 |
| EP1939197A1 (en) | 2008-07-02 |
| AR064657A1 (es) | 2009-04-15 |
| EP2097415A1 (en) | 2009-09-09 |
| AU2007338413A1 (en) | 2008-07-03 |
| BRPI0720419A2 (pt) | 2013-12-31 |
| CA2672692A1 (en) | 2008-07-03 |
| UY30835A1 (es) | 2008-07-31 |
| US8044061B2 (en) | 2011-10-25 |
| WO2008077557A8 (en) | 2009-05-22 |
| CN101631788A (zh) | 2010-01-20 |
| EP2097415B1 (en) | 2014-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6210727A2 (es) | Derivados de 8 etinilxantina como antagonistas de receptores de a2a selectivos | |
| CL2016002942A1 (es) | Nuevos derivados de pirazolina pirimidina y su uso como inhibidores de malt1 | |
| PE20190656A1 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
| PE20200388A1 (es) | Amidas heterociclicas de 5 miembros y biciclicas como inhibidores de rock | |
| EA201400701A1 (ru) | Замещенные соединения пиразоло[1,5-a]пиридина в качестве ингибиторов тропомиозинрецепторной киназы (trk) | |
| CU20200051A7 (es) | Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5 | |
| EA201591204A3 (ru) | Новые хиральные n-ацил-5,6,7,(8-замещенные)-тетрагидро-[1,2,4]триазоло[4,3-а]пиразины как селективные антагонисты рецептора nk-3, фармацевтическая композиция, способы применения при нарушениях, опосредованных nk-3 рецепторами, и их хиральный синтез | |
| AR079553A1 (es) | Derivados de diaza-espiro-[5,5]-undecanos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos del snc, tales como trastornos del sueno y de la dependencia,entre otros. | |
| AR065354A1 (es) | Derivados de 2-aminopirimidina, un metodo para su preparacion, una composicion farmaceutica que lo comprende y su uso en el tratamiento de enfermedades mediadas por el receptor de histamina h4. | |
| UY33337A (es) | DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS | |
| BRPI1009333B8 (pt) | compostos inibidores de beta-secretase, seus usos, bem como composição farmacêutica | |
| ECSP12011910A (es) | Derivados de imidazopiridina como inhibidores de jak | |
| AR078504A1 (es) | Compuestos eficaces como inhibidores de la xantina-oxidasa, metodo para la preparacion de los mismos y composicion farmaceutica que los contiene | |
| DK3489238T3 (da) | Farmaceutiske sammensætninger af 6h-pyrido[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5-on- og [1,2,4]triazolo[1,5-c]pteridin-5(6h)-on-derivater som pde1-inhibitorer til behandling af for eksempel neurologiske lidelser | |
| NO20071522L (no) | Fremgangsmate for fremstilling av kirale 8-(3-amino-piperidin-1-yl)-xantiner | |
| NO20073720L (no) | Heterocyklisk substituerte fenylmetanoner som inhibitorer av glycintransportorer | |
| ECSP088891A (es) | Derivados bicíclicos como inhibidores de cetp | |
| PT2421879E (pt) | Novos 7-deazapurina nucleósidos para utilizações terapêuticas | |
| EA201890547A1 (ru) | Способ получения ингибитора parp, кристаллические формы и их применения | |
| WO2009043320A3 (en) | Substituted 6-(alkylbenzylamino)purine derivatives for use as cytokinin receptor antagonists and preparations containing these derivatives | |
| CO6230982A2 (es) | Compuestos triciclicos que contienen actividad antagonista de factor de liberacion de corticotropina y composiciones farmaceuticas que los contienen | |
| EA201270339A1 (ru) | Замещенные производные ксантина | |
| AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| NI200900134A (es) | Derivados de imidazol como inhibidores de proteína de huso de cinesina (eg-5). | |
| BR112015012720A2 (pt) | derivados de feniletilpiridina como inibidores de pde4 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Application withdrawn |